Ann: Prescient completes acquisition of AKTivate Therapeutics, page-4

An interesting question worth asking.

Not sure how lofty the sums were though. I would have thought they were potentially lofty sums, dependent on SP.

IMO it comes down to what he does for the dough. How Exec can this Exec Director be, given his wide range of other related business interests? What would he be doing for his $180k? How much time can he realistically devote to PTX/VHL? How will we know his efforts were worth the price?

There are plenty of teats in Biotech just waiting to be sucked on. Only a great deal more information on his role or the test of time will tell us if $180k is good value for money or if PTX is yet another board-controlled udder, like so many others in the sector.